<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128401</url>
  </required_header>
  <id_info>
    <org_study_id>050198</org_study_id>
    <secondary_id>05-M-0198</secondary_id>
    <nct_id>NCT00128401</nct_id>
  </id_info>
  <brief_title>Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia</brief_title>
  <official_title>Effect of D-Cycloserine on Treatment of Social Phobia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study examines whether an antibiotic, d-cycloserine (DCS), boosts the effectiveness of&#xD;
      cognitive behavior therapy (CBT) for social anxiety. CBT has been shown to be effective for&#xD;
      the treatment of social anxiety in children and adults, but even after treatment,&#xD;
      approximately 40% may remain diagnosable. The antibiotic DCS has been shown to enhance the&#xD;
      type of learning that is promoted by exposure therapy, a main component of CBT. This study&#xD;
      will test whether DCS can improve the effectiveness of CBT for social anxiety.&#xD;
&#xD;
      All participants will receive 12 weekly CBT sessions. In addition to receiving the CBT,&#xD;
      participants will be randomly assigned (similar to a coin toss) to receive either DCS or a&#xD;
      placebo (sugar pill). The pill will be taken 1-2 hours prior to each of the 12 CBT sessions.&#xD;
      The pill is taken only on the 12 therapy days.&#xD;
&#xD;
      Prior to receiving treatment, participants will be asked to:&#xD;
&#xD;
        -  participate in interviews to assess diagnosis and how they are doing including mood,&#xD;
           degree of nervousness and behavior&#xD;
&#xD;
        -  have a physical examination, a urine test, and an electrocardiogram (EKG)&#xD;
&#xD;
        -  undergo tests involving problem-solving and memory&#xD;
&#xD;
        -  prepare and present a speech to a &quot;virtual audience&quot; using virtual reality goggles&#xD;
&#xD;
        -  undergo functional magnetic resonance imaging (fMRI) while performing tasks that involve&#xD;
           looking at pictures, remembering things, testing reaction times, and making simple&#xD;
           choices&#xD;
&#xD;
      Those who have not improved by the end of the study will be offered standard antianxiety&#xD;
      medication treatment for 1 to 3 months. If a participant does not wish to take medication,&#xD;
      study clinicians will help him/her locate psychological care in the community. Participants&#xD;
      will be asked to complete a follow-up assessment 3 months after their last CBT session.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Social phobia afflicts between 3%-15% of the US population. As such, it is a particularly&#xD;
      common debilitating psychiatric disorder. Like many anxiety disorders, social phobia&#xD;
      typically arises during adolescence. Treatment has consisted of medication or cognitive&#xD;
      behavioral therapy (CBT). Selective Serotonin Reuptake Inhibitors (SSRIs) represent the&#xD;
      first-line pharmacological treatment both in adults as well as adolescents (APA Treatment&#xD;
      Guidelines 2004). Similarly, CBT significantly improves outcome in both age groups. This&#xD;
      treatment consists of psychoeducation, exposure therapy, and cognitive restructuring. While&#xD;
      both treatments produce clinically meaningful benefits, most patients exhibiting positive&#xD;
      responses to these treatments continue to exhibit marked residual symptoms, if not full-blown&#xD;
      anxiety disorders. Thus, there is great need for treatment advances.&#xD;
&#xD;
      Intense fear of social scrutiny represents a core component of social phobia, and extinction&#xD;
      of this fear represents the goal of exposure therapy during CBT (Cohn and Hope). Finding&#xD;
      treatments that facilitate extinction is of paramount importance. In animals, extinction&#xD;
      involves an active learning process that is blocked by glutamatergic NMDA antagonists and&#xD;
      facilitated by NMDA agonists. Specifically, administration of D-cycloserine (DCS), a partial&#xD;
      agonist at the glycine modulatory site on the NMDA receptor, produces a dose-dependent&#xD;
      facilitation of extinction in the rat. As such, DCS might facilitate extinction during&#xD;
      exposure-based CBT. Indeed, Ressler (Ressler et al 2004) recently reported preliminary data&#xD;
      from a clinical trial supporting this hypothesis.&#xD;
&#xD;
      We will examine the degree to which DCS treatment can augment the clinical response in social&#xD;
      phobia to CBT-exposure-based therapy. Specifically, we will study two groups of individuals&#xD;
      with social phobia, both of whom will receive CBT. One group will receive placebo; a second&#xD;
      group will receive 50 mg of D-cycloserine 1-2 hours before each exposure therapy session. We&#xD;
      hypothesize that compared to placebo, DCS will produce greater reductions in social anxiety&#xD;
      symptoms following CBT treatment. Finally, given that chronic social anxiety disorder&#xD;
      virtually always begins during childhood, it is particularly vital to develop early&#xD;
      interventions for the disorder. Accordingly, our trial will examine both adolescents and&#xD;
      adults with the disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Improvement (CGI-S) Scale</measure>
    <time_frame>12 weeks post baseline</time_frame>
    <description>Symptom severity and improvement was assessed using the Clinical Global Impressions scale (CGI). It is a 2-item clinician-administered instrument that measures the patients' illness severity and global improvement. The minimum value for the CGI is 1=Normal, not at all ill and the maximum value is 7=Among the most extremely ill patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liebowitz Social Anxiety Scale (LSAS)</measure>
    <time_frame>12 weeks post baseline</time_frame>
    <description>Social anxiety symptoms were assessed using the Liebowitz Social Anxiety Scale (LSAS). It is a 24-item self-report instrument that measures overall social anxiety fear and avoidance symptoms. This is the baseline assessment. The 24 items are each rated twice, from a &quot;0&quot; to &quot;3&quot; scale, with &quot;0&quot; indicated no level of symptom and &quot;3&quot; indicating a high level of the system. One rating is for anxiety, and the other is for avoidance. Thus, the lowest possible score is 0, and the highest possible score is 144. The total score represents the simple sum of all 48 ratings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Phobic Disorders</condition>
  <condition>Anxiety</condition>
  <condition>Social Phobia</condition>
  <arm_group>
    <arm_group_label>D-Cycloserine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An antibiotic, d-cycloserine (DCS) was given to one group and the group is evaluated to see if the drug boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Another group was given the placebo and tested for effectiveness of cognitive behavior therapy (CBT) for social anxiety.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-Cycloserine</intervention_name>
    <arm_group_label>D-Cycloserine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Subjects between 8 yrs of age (preadolescents) and under 55 yrs of age.&#xD;
&#xD;
               2. Subjects medically healthy.&#xD;
&#xD;
               3. Able to give informed consent.&#xD;
&#xD;
               4. Not on psychotropic meds for a minimum of 6 weeks for fluoxetine; a minimum of 1&#xD;
                  week for PRN benzodiazepines and beta blockers, and a minimum of 3 weeks for all&#xD;
                  other psychotropic meds.&#xD;
&#xD;
               5. Subjects diagnosed with DSM IV symptoms of social phobia, generalized or specific&#xD;
                  type.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Current major depressive disorder.&#xD;
&#xD;
          2. Lifetime diagnosis of psychotic disorder, bipolar disorder, eating disorder, mental&#xD;
             retardation, substance or alcohol dependence (other than nicotine); active suicidal&#xD;
             ideation.&#xD;
&#xD;
          3. Current or lifetime history of a neurological disorder (other than tic disorders,&#xD;
             febrile seizures of infancy), seizure disorder.&#xD;
&#xD;
          4. Any unstable medical condition.&#xD;
&#xD;
          5. Use of any psychoactive substance in the past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer A Cameron, C.R.N.P.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2005-M-0198.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Alström JE, Nordlund CL, Persson G, Hårding M, Ljungqvist C. Effects of four treatment methods on social phobic patients not suitable for insight-oriented psychotherapy. Acta Psychiatr Scand. 1984 Aug;70(2):97-110.</citation>
    <PMID>6148843</PMID>
  </reference>
  <reference>
    <citation>Butler G, Cullington A, Munby M, Amies P, Gelder M. Exposure and anxiety management in the treatment of social phobia. J Consult Clin Psychol. 1984 Aug;52(4):642-50.</citation>
    <PMID>6147366</PMID>
  </reference>
  <reference>
    <citation>D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry. 2000 Mar 1;47(5):450-62.</citation>
    <PMID>10704956</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2005</study_first_posted>
  <results_first_submitted>July 1, 2013</results_first_submitted>
  <results_first_submitted_qc>April 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2014</results_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive</keyword>
  <keyword>Behavioral</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Therapy</keyword>
  <keyword>Extinction</keyword>
  <keyword>Social Phobia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phobic Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>9 participants were enrolled, but not assigned to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>D-cycloserine</title>
          <description>Subjects were randomized to receive cognitive behavioral therapy with augmentation of D-cycloserine 50 mg administered on day of therapy session. All subjects underwent the same intake procedures and the same procedures for the assessments for baseline severity. Morever all subjects began the same psychotherapy procedures using cognitive behavioral therapy. After cognitive behavioral therapy was initiated subjects were randomized into a 1:1 ratio by the NIH pharmacy to enter either continued therapy with placebo or continued therapy with the active agent.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects were randomized to receive cognitive behavioral therapy with augmentation of placebo administered on day of therapy session.&#xD;
All subjects underwent the same intake procedures and the same procedures for the assessments for baseline severity. Morever all subjects began the same psychotherapy procedures using cognitive behavioral therapy. After cognitive behavioral therapy was initiated subjects were randomized into a 1:1 ratio by the NIH pharmacy to enter either continued therapy with placebo or continued therapy with the active agent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline mean and SD for CGI outcome measure was captured for 42 subjects only. The baseline mean and SD for LSAS outcome measure was captured for 40 subjects. Only 39 subjects were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>D-cycloserine</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impressions (CGI) - baseline</title>
          <description>Symptom severity and improvement was assessed using the Clinical Global Impressions scale (CGI). It is a 2-item clinician-administered instrument that measures severity and improvement. One item characterizes subjects at baseline and at each post-baseline visit, based on severity. This is the CGI-S scale. This scale ranges from a score of 1 (normal, not all ill) to 7 (among the most extremely ill patients). The second item, the primary efficacy measure, is only rated after baseline, to quantify the amount of change. This ranges from 1 (completely recovered) to 8 (much worse).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.35" spread="0.587"/>
                    <measurement group_id="B2" value="4.278" spread="0.576"/>
                    <measurement group_id="B3" value="4.286" spread="0.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liebowitz Social Anxiety Scale (LSAS) - baseline</title>
          <description>Social anxiety symptoms were assessed using the Liebowitz Social Anxiety Scale (LSAS). It is a 24-item self-report instrument that measures overall social anxiety fear and avoidance symptoms. This is the baseline assessment. The 24 items are each rated twice, from a &quot;0&quot; to &quot;3&quot; scale, with &quot;0&quot; indicated no level of symptom and &quot;3&quot; indicating a high level of the system. One rating is for anxiety, and the other is for avoidance. Thus, the lowest possible score is 0, and the highest possible score is 144. The total score represents the simple sum of all 48 ratings.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.9" spread="27.028"/>
                    <measurement group_id="B2" value="75.588" spread="25.063"/>
                    <measurement group_id="B3" value="83.725" spread="25.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Improvement (CGI-S) Scale</title>
        <description>Symptom severity and improvement was assessed using the Clinical Global Impressions scale (CGI). It is a 2-item clinician-administered instrument that measures the patients' illness severity and global improvement. The minimum value for the CGI is 1=Normal, not at all ill and the maximum value is 7=Among the most extremely ill patients.</description>
        <time_frame>12 weeks post baseline</time_frame>
        <population>The analyses included only those subjects who were assigned to the DCS condition and placebo</population>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Improvement (CGI-S) Scale</title>
          <description>Symptom severity and improvement was assessed using the Clinical Global Impressions scale (CGI). It is a 2-item clinician-administered instrument that measures the patients' illness severity and global improvement. The minimum value for the CGI is 1=Normal, not at all ill and the maximum value is 7=Among the most extremely ill patients.</description>
          <population>The analyses included only those subjects who were assigned to the DCS condition and placebo</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.167" spread="0.577"/>
                    <measurement group_id="O2" value="3.833" spread="0.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liebowitz Social Anxiety Scale (LSAS)</title>
        <description>Social anxiety symptoms were assessed using the Liebowitz Social Anxiety Scale (LSAS). It is a 24-item self-report instrument that measures overall social anxiety fear and avoidance symptoms. This is the baseline assessment. The 24 items are each rated twice, from a &quot;0&quot; to &quot;3&quot; scale, with &quot;0&quot; indicated no level of symptom and &quot;3&quot; indicating a high level of the system. One rating is for anxiety, and the other is for avoidance. Thus, the lowest possible score is 0, and the highest possible score is 144. The total score represents the simple sum of all 48 ratings.</description>
        <time_frame>12 weeks post baseline</time_frame>
        <population>The analyses included only those subjects who were assigned to the DCS condition and placebo</population>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Liebowitz Social Anxiety Scale (LSAS)</title>
          <description>Social anxiety symptoms were assessed using the Liebowitz Social Anxiety Scale (LSAS). It is a 24-item self-report instrument that measures overall social anxiety fear and avoidance symptoms. This is the baseline assessment. The 24 items are each rated twice, from a &quot;0&quot; to &quot;3&quot; scale, with &quot;0&quot; indicated no level of symptom and &quot;3&quot; indicating a high level of the system. One rating is for anxiety, and the other is for avoidance. Thus, the lowest possible score is 0, and the highest possible score is 144. The total score represents the simple sum of all 48 ratings.</description>
          <population>The analyses included only those subjects who were assigned to the DCS condition and placebo</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.417" spread="28.804"/>
                    <measurement group_id="O2" value="56.154" spread="20.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>D-cycloserine</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
        <group group_id="E3">
          <title>Not Assigned</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial and genetic disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders - Other, specify (Thyroid problem)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify (Cold symptoms)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify (Cold)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify (congestion)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify (missed medication)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify (missed treatment session)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify (Runny nose)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify (stopped medication)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify (tail bone cyst)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify (broken left arm)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus (Itching from broken arm)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The baseline mean and SD for CGI outcome measure was captured for 42 subjects only. The baseline mean and SD for LSAS outcome measure was captured for 40 subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cameron, Jennifer Ann</name_or_title>
      <organization>National Institute of Mental Health</organization>
      <phone>+1 301 402 9356</phone>
      <email>cameronj@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

